Ann: AGM Presentation, page-8

First 8 Last

Share
Profile

Follow
kingkev

28,068 Posts.

1408

26/05/20

08:29

Post #: 44830823
Share

Originally posted by edshann: ↑

My take was nothing much new was said and certainly nothing to excite the market.

My interpretation of the comment on Zeep was it worked in the lab, but making it commercial could take a while.

On the accounts cash declined from $15 million at Dec 31 to $9.4 million at 31 March and in the absence of the placement would have declined further to $8.8 million at 25 May (assuming the $0.8 million cost of the raising has been paid).

I also found interesting the cash flow table. There are sales of $50 million, cash receipts from customers at end Dec are only $40 million and receivables grow from $17 million at end 2019 to $27 million at end 2020. Net cash (operating and capital) is actually negative by $2.2 million over 2020, before the capital raising. That presumably reflects the bulk of work being done in the second half of the year and lagged cash receipts. The half year cash flow at 30 June, excluding the placement will not be flash. That is not really surprising given covid and explains the need for the sudden cash raising.

I asked whether the range of forecast receipts for Chinese other projects of $9-18 million and $4.5-9 million new international projects was a range for certain projects, or whether possible but not certain projects were also included. It was not answered live, but all questions are supposed to be answered on the website, so I will wait and see.

I note that the total forecast sales range is unchanged at $50-70 million. However, Chinese sales are estimated at $40-55 million and international sales total is around $10 million, which implies the top end of the range is unlikely. I suspect the bottom end of the range is more likely. The certain Chinese projects bottom range is $45 million (assuming $2 million for Dianchi trials) and the international bottom range is $10.5 million (and covid could delay some of these), suggesting the "certain" total sales are only just over $50 million.

Lachie mentioned that the trial on Dianchi was small. I assume that means the main impact if it proceeds after the trial will be in 2021.

Expand

not sure they hit targets last time around..........this time around it could be touch and go

Last time I spoke with the company about ZEEP it was as you said.........we have it, it works but commercializing it will take time as they test various engineering options.

PET Price at posting: 55.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

What each US election outcome would mean for Australian companies & investors

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Making money: How many microcaps should be in an investor's portfolio?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?